Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia

Biologics: Targets and Therapy

Volumn 2, Issue 3, 2008, Pages 491-500

  Karp, Judith E ^a   Lancet, Jeffrey E ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Acute myelogenous leukemia (AML); Farnesylation; Farnesyltransferase inhibitor; Gene expression; Signal transduction; Tipifarnib

Indexed keywords

EID: 77952291716     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s3485     Document Type: Review

References (76)

1. Ahel I, Rass U, El-Khamisy SF, et al. 2006 The neurodegenerative disease protein aprataxin resolves abortive DNA ligation intermediates. Nature, 443:713-6.
2. Appelbaum FR, Gundacker H, Head DR, et al. 2006 Age and acute myeloid leukemia. Blood, 107:3481-5.
3. Arber DA, Stein AS, Carter NH, et al. 2003. Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. Am J Clin Pathol, 119:672-80.
4. Archimbaud E, Jehn U, Thomas X, et al. 1999. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leukemia, 13:843-9.
5. Basso AD, Kirschmeier P, Bishop WR. 2006. Farnesyltransferase inhibitors. J Lipid Res, 47:15-31.
6. Beaupre DM, Cepero E, Obeng EA, et al. 2004. R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. Mol Cancer Therap, 3:179-86.
7. Bishop JF, Lowenthal RM, Joshua D, et al. 1990. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood, 75:27-32.
8. Bolanos-Meade J, Karp JE, Guo C, et al. 2003. Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide. Leuk Res, 27:313-21.
9. Brandwein JM, Leber BF, Howson-Jan K, et al. 2007. A Phase I study of tipifarnib in combination with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia age 60 and over [abstract]. Blood, 110:274a (abstract 899).
10. Breems DA, Van Putten WLJ, Huijgens PC, et al. 2005. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol, 23:1969-78.
11. Bruzek LM, Poynter JN, Kaufmann SH, et al. 2005. Characterization of a human carcinoma cell line selected for resistance to farnesyltransferase inhibitors. Mol Pharmacol, 68:477-86.
12. Buchner T, Berdel WE, Schoch C, et al. 2006. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol, 24:2480-9.
13. Bullinger L, Dohner K, Bair E, et al. 2004. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. New Engl J Med, 350:1605-16.
14. Buzzeo R, Enkemann S, Nimmanapalli R, et al. 2005. Characterization of a R115777-resistant human multiple myeloma cell line with crossresistance to PS-341. Clin Cancer Res, 11:6057-64.
15. Cassileth PA, Lynch E, Hines JD, et al. 1992. Varying intensity of postremission therapy in acute myeloid leukemia. Blood, 79:1924-30.
16. Castro AF, Rebhun JF, Clark GJ, et al. 2003 Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycinand farnesylation-dependent manner. J Biol Chem, 278:32493-6.
17. Cortes J, Albitar M, Thomas D, et al. 2003. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood, 101:1692-7.
18. Delmonte J, Kantarjian HM, Garcia-Manero G, et al. 2007. Final update of Phase I-II study of the farnesyltransferase inhibitor tipifarnib in combination with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplasia [abstract]. Blood, 110:136a (abstract 441).
19. Del Villar K, Urano J, Guo L, et al. 1999. A mutant form of protein farnesyltransferase exhibits increase resistance to farnesyltransferase inhibitors. J Biol Chem, 274:27010-17.
20. End DW. 1999. Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway. Invest New Drugs, 17:241-58.
21. Erba HP, Kopecky KJ, Kirschbaum MH, et al. 2007. Phase II studies of different schedules and doses of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra, NSC 702818) for patients of age 70 or older with previously untreated acute myeloid leukemia (AML): A North American Intergroup study (S0432) [abstract]. Blood, 110:136a (abstract 440).
22. Estey E. 2007. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol, 25:1908-15.
23. Evans JPM, Prentice HG. 1982. Remission induction in acute myeloid leukaemia with oral etoposide. Lancet, 2(8311):1345-6.
24. Feldkamp MM, Lau N, Guha A. 1999. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene, 18:7514-26.
25. Fenaux P, Raza A, Mufti G, et al. 2007. A multicenter phase 2 study of the Farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood, 109:4158-63.
26. Fiegl M. Buchner T, Hiddemann W, et al. 2005. A phase I/II study of oral etoposide and idarubicin in elderly patients with high-risk acute myeloid leukemia unable to undergo intensive chemotherapy. Ann Hematol, 84:227-31.
27. Foisner R, Traub P, Wiche G. 1991. Protein kinase A- and protein kinase C-regulated interaction of plectin with lamin B and vimentin. Proc Natl Acad Sci USA, 88:3812-16.
28. Fong LG, Frost D, Meta M, et al. 2006. A protein Farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science, 311:1621-3.
29. Goemans BF, Zwaan CM, Harlow A, et al. 2005 In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. Blood, 106:3532-7.
30. Goldstone AH, Burnett AK, Wheatley K, et al. 2001. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML 11 trial. Blood, 98:1302-11.
31. Gomez-Benito M, Marzo I, Anel A, et al. 2005. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination. Mol Pharmacol, 67:1991-8.
32. Grimwade D, Walker H, Harrison G, et al. 2001. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood, 98:1312-20.
33. Harris NL, Jaffe ES, Diebold J, et al. 1997. World Health Organization classification of neoplastic diseases of the hematopoeitic and lymphoid tissues: report of the clinical advisory committee meeting - Airlie House, Virginia, November. J Clin Oncol, 17:3835-49.
34. Harousseau J-L, Lancet JE, Reiffers J, et al. 2007a. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relasped acute myeloid leukemia. Blood, 109:5151-6.
35. Harousseau J-L, Martinelli G, Jedrejczak WW, et al. 2007b. A randomized Phase 3 study of tipifarnib compared to best supportive care (including hydroxyurea) in the treatment of newly diagnosed acute myeloid leukemia (AML) in patients 70 or older. Blood, 110:135a (abstract 439).
36. Jackson GH, Taylor PR, Iqbal A, et al. 1997. The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacy. Leukemia, 11:1193-6.
37. Jiang K, Coppola D, Crespo NC, et al. 2000. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol, 20:139-48.
38. Karp JE, Lancet JE, Kaufmann SH, et al. 2001. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinical-laboratory correlative trial. Blood, 97:3361-9.
39. Karp JE, Feldman EJ, Morris LE, et al. 2006. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia (AML): phase I trial of oral tipifarnib (T) combined with oral etoposide (E) for adults ≥age 70 who are not candidates for traditional cytotoxic chemotherapy. Blood, 108:130a.
40. Karp JE, Lancet JE. 2007. Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies. Cancer Investig, 25:484-94.
41. Kirschbaum MH, Selwyn Stein A, Tuscano J, et al. 2007. A Phase I study of the farnesyltransferase inhibitor tipifarnib in a week-on week-off dose schedule in acute myelogenous leukemia [abstract]. Blood, 110:182a (abstract 891).
42. Korycka A, Smolewski P, Robak T. 2004. The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro [abstract]. Eur J Haematol, 73:418-26.
43. Kurzrock R, Kantarjian HM, Cortes JE, et al. 2003. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the Phase 1 setting. Blood, 102:4527-34.
44. Kurzrock R, Albitar M, Cortes JE, et al. 2004. Phase II study of R115777, a farnesyltransferase inhibitor, in myelodysplastic syndrome. J Clin Oncol, 22:1287-92.
45. Lancet JE, Willman CL, Bennett JM. 2000. Acute myelogenous leukemia and aging: clinical interactions. Hematol Oncol North Am, 14:251-67.
46. Lancet JE, Gojo I, Gotlib J, et al. 2007. A phase II study of the Farnesyltransferase inhibitor Tipifarnib in elderly patients with previously untreated poor-risk acute myelogenous leukemia. Blood, 109:1387-94.
47. Leith CP, Kopecky KJ, Chen IM, et al. 1999. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group study. Blood, 94:1086-99.
48. Li TK, Liu LF. 2001. Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol, 41:53-77.
49. Lowenberg B, Suici S, Archimbaud E, et al. 1998. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cyatarbine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group randomized phase III study AML-9. J Clin Oncol, 16:872-81.
50. Mahadevan D, List AF. 2004. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood, 104:1940-51.
51. Manning BD, Cantley LC. 2003. Rheb fills a GAP between TSC and TOR. Trends Biochem Sci, 28:573-6.
52. Mrozek K, Marcucci G, Paschka P, et al. 2007. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood, 109:431-48.
53. Medeiros BC, Landau HJ, Morrow M, et al. 2007. The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines. Leukemia, 21:739-46.
54. Mesa RA, Camoriano JK, Geyer SM, et al. 2007. A Phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia, 21:1964-70.
55. Morgan MA, Reuter CW. 2006. Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias. Ann Hematol, 85:139-63.
56. Oriol A, Ribera J-M, Brunet S, et al. 2003. Oral induction and consolidation chemotherapy with idarubicin and etoposide in elderly patients with acute myeloid leukemia. Haematologica, 88:229-30.
57. Prendergast GC, Davide JP, Lebowitz PF, et al. 1996. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyltransferase inhibitors. Cancer Res, 56:2626-32.
58. Radmacher MD, Marcucci G, Ruppert AS, et al. 2006. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Croup B study. Blood, 108:1677-83.
59. Raponi M, Belly RT, Karp JE, et al. 2004. Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer, 4:56.
60. Raponi M, Harousseau JL, Lancet JE, et al. 2007. Identification of molecular predictors of repsonse in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res, 13:2254-60.
61. Raponi M, Lancet JE, Fan H, et al. 2008. A two-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood, 111:2589-96.
62. Raz T, Nardi V, Azam M, et al. 2007. Resistance to the farnesyl transferase inhibitor SCH66336 (Lonafarnib) caused by mutations in the target protein farnesyl transferase beta. Blood, 110:2102-9.
63. Reuter CWM, Morgan MA, Bergmann L. 2000. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood, 96:1655-69.
64. Sebti SM, Der CJ. 2003. Searching for the elusive targets of Farnesyltransferase inhibitors. Nat Rev, 3:945-51.
65. Sebti SM, Adjei AA. 2004. Farnesyltransferase inhibitors. Semin Oncol, 31:28-39.
66. Smith V, Rowlands MG, Barrie E, et al. 2002. Establishment and characterization of acquired resistance to farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line. Clin Cancer Res, 8:2002-9.
67. Stone RM, Berg DT, George SL, et al. 2001. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood, 98:548-53.
68. Toksoz D, Williams DA. 1994. Novel human oncogene lbc detected by transfection with distinct homology regions to signal transduction proteins. Oncogene, 9:621-8.
69. Tsai MY, Wang S, Heidinger JM, et al. 2006. A mitotic lamin B matrix induced by RanGTP required for spindle assembly. Science, 311:1887-93.
70. Wang JC. 2002. Cellular roles of DNA topoisomerases: a molecular. Nat Rev Mol Cell Biol, 3:430-40.
71. Wilson CS, Davidson GS, Martin SB, et al. 2006. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood, 108:685-96.
72. Witzig TE, Kaufmann SH. 2006. Inhibition of the phosphatidylinositol- 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol, 7:285-94.
73. Yanada M, Suzuki M, Kawashima K, et al. 2005. Long-term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: a single center experience. Eur J Hematol,74:418-23.
74. Yanamandra N, Colaco NM, Parquet NA, et al. 2006. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res, 12:591-9.
75. Zhang B, Groffen J, Heisterkamp N. 2005. Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a. Blood, 106:1355-61.
76. Zheng Y, Olson MF, Hall A, et al. 1995. Direct involvement of the small GTP-binding protein Rho in lbc oncogene function. J Biol Chem, 270: 9031-4.